VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+81.16%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$2.1B
AUM Growth
+$2.1B
(+44%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-2.4%
Top 10 Holdings %
Top 10 Hldgs %
63.64%
Holding
44
New
8
Increased
14
Reduced
7
Closed
6
Top Buys
| 1 |
Ocular Therapeutix
OCUL
|
$45.4M |
| 2 |
enGene Holdings
ENGN
|
$43.5M |
| 3 |
Dianthus Therapeutics
DNTH
|
$35M |
| 4 |
Edgewise Therapeutics
EWTX
|
$33.2M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$31.1M |
Top Sells
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$251M |
| 2 |
Adverum Biotechnologies
ADVM
|
$50.8M |
| 3 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$29.5M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$22.8M |
| 5 |
Celcuity
CELC
|
$19.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Adverum Biotechnologies
ADVM
$64.6M
| $22M | 1.05% | 1,556,419 -3,591,128 | -70% | -$50.8M |
|
|
27
Celcuity
CELC
$2.17B
| $21M | 1% | 970,000 -915,538 | -49% | -$19.8M |
|
|
ABVX
28
Abivax
ABVX
$6.12B
| $19.2M | 0.92% | 1,345,780 +347,210 | +35% | +$4.97M |
|
29
Immatics
IMTX
$619M
| $18.4M | 0.87% | +1,750,000 | New | +$18.4M |
|
30
Lyra Therapeutics
LYRA
$11.5M
| $16M | 0.76% | 2,576,093 +500 | +0% | +$3.11K |
|
31
CG Oncology
CGON
$2.04B
| $15.4M | 0.73% | +350,000 | New | +$15.4M |
|
32
Century Therapeutics
IPSC
$42.5M
| $14.2M | 0.68% | +3,405,133 | New | +$14.2M |
|
33
Trevi Therapeutics
TRVI
$883M
| $11.8M | 0.56% | 3,422,675 +278 | +0% | +$959 |
|
34
Tenaya Therapeutics
TNYA
$184M
| $8.14M | 0.39% | +1,555,556 | New | +$8.14M |
|
35
Mineralys Therapeutics
MLYS
$1.03B
| $7.17M | 0.34% | +555,554 | New | +$7.17M |
|
|
SLRN
36
DELISTED
ACELYRIN
SLRN
| $6.33M | 0.3% | 937,113 | – | – |
|
37
EyePoint Pharmaceuticals
EYPT
$797M
| $5.17M | 0.25% | 250,000 | – | – |
|
38
Olema Pharmaceuticals
OLMA
$375M
| $872K | 0.04% | 77,042 | – | – |
|
39
GH Research
GHRS
$837M
| – | – | -1,318,327 | Closed | -$7.65M |
|
40
Milestone Pharmaceuticals
MIST
$156M
| – | – | -925,048 | Closed | -$1.54M |
|
|
41
Rhythm Pharmaceuticals
RYTM
$6.85B
| – | – | -495,983 | Closed | -$22.8M |
|
42
Savara
SVRA
$567M
| – | – | -3,500,000 | Closed | -$16.5M |
|
|
AMAM
43
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| – | – | -2,070,000 | Closed | -$29.5M |
|
|
RYZB
44
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – | -4,030,471 | Closed | -$251M |
|